...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >The effect of Verapamil in Malaria ? A Prospective Randomized Double Blind Control Clinical Study
【24h】

The effect of Verapamil in Malaria ? A Prospective Randomized Double Blind Control Clinical Study

机译：维拉帕米在疟疾中的作用？前瞻性随机双盲对照临床研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Context: To reduce the drug resistance produced by malarial parasites to chloroquine and Verapamil, a chemosensitiser which has been tried in vivo. Objectives: To find out whether verapamil facilitates the action of chloroquine in malaria and to find out the safety of using verapamil in malaria. Study Design: A double blind randomized control studyDescription of the Subjects: Sixty patients who were positive for malaria by the QBC test (vivax, falciparum) without any associated illness (hypertension, diabetes, anaemia, cardiac, renal diseases) were included. Informed consent was obtained from each patient. Interventions: After thorough clinical examination, the patients were randomly allocated for two different treatments. Group A received standard chloroquine therapy (600 mg loading dose, 300 mg after 8 hrs, 24 hrs and 48 hrs). Group B received in addition to chloroquine therapy, verapamil 40 mg orally two hours after the administration of chloroquine. All the patients were evaluated, based on the time taken for the temperature to become normal, disappearance of rigor and chills (patients were evaluated at every 4th hour ) and the QBC test to become negative (test done at every 12th hour ) Results: It was observed that patients in group B had earlier relief of symptoms and signs and QBC became negative early as compared to group A. Fever (Mean?18.53 hours for group A and 9.33 hours for group B, SD for group A is 7.68 hours and for group B is 3.53 hours)and rigor and chills (Mean for group A is 18.8 hours and group B is 9.7 hours, SD for group A is 7.94 hours and for group B is 3.53 hours) were reduced to normal within 24 hours in group B, whereas in group A, it became normal only in 36 hours. Parasitaemia was cleared in 36 hours in group B, but in group A, it was cleared only in 48 hours (Mean for group A is 28.4 hours and for group B is 19.7 hours, SD for group A is 7.68 hours and for group B is 6.81 hours). No one had hypotension or any other significant adverse effects. The results were analyzed by the Student?s t test and they was considered to be significant (p<0.001). Conclusion: Verapamil facilitates the action of chloroquine in malaria and it is safe.
机译：背景：为降低疟疾寄生虫对氯喹和维拉帕米（一种已经在体内尝试过的化学增敏剂）产生的耐药性。目的：确定维拉帕米是否可促进氯喹在疟疾中的作用，并确定在维拉帕米中使用维拉帕米的安全性。研究设计：一项双盲随机对照研究对象的描述：包括60例通过QBC测试呈阳性的疟疾（间日病毒，恶性疟）且无任何相关疾病（高血压，糖尿病，贫血，心脏，肾脏疾病）的患者。从每位患者获得知情同意。干预措施：经过全面的临床检查，患者被随机分配接受两种不同的治疗。 A组接受标准的氯喹治疗（600 mg负荷剂量，8小时，24小时和48小时后300 mg）。 B组除接受氯喹治疗外，于服用氯喹后2小时口服维拉帕米40 mg。根据温度恢复正常所需的时间，严酷和寒冷的消失（每4小时对患者进行评估）和QBC测试变为阴性（每12小时进行测试）评估所有患者。结果：观察到B组患者的症状和体征比A组更早缓解，并且QBC较A组早变。发烧（A组平均为18.53小时，B组平均为9.33小时，A组的SD为7.68小时， B组为3.53小时）和严酷和寒冷（A组的平均时间为18.8小时，B组的平均时间为9.7小时，A组的SD为7.94小时，B组的SD为3.53小时）在B组中在24小时内降至正常，而在A组中，仅在36小时内恢复正常。 B组在36小时内清除了寄生虫血症，但A组仅在48小时内清除（A组的平均值为28.4小时，B组的平均值为19.7小时，A组的SD为7.68小时，B组的SD为7.68小时）。 6.81小时）。没有人有低血压或其他严重不良反应。结果通过Student's t检验进行了分析，被认为是有意义的（p <0.001）。结论：维拉帕米可促进氯喹在疟疾中的作用，并且是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号